Loading…
TG Therapeutics, Inc. is projected to rise to $55.28 by 2027, a +41% move from its current price of $39.20. TGTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $38.30 | $39.20 | $40.12 | 0.00% |
| May 30 | $37.93 | $39.20 | $40.51 | 0.00% |
| May 31 | $37.65 | $39.20 | $40.81 | 0.00% |
| Jun 1 | $37.42 | $39.20 | $41.07 | 0.00% |
| Jun 2 | $37.21 | $39.20 | $41.29 | 0.00% |
| Jun 3 | $37.03 | $39.20 | $41.50 | 0.00% |
| Jun 4 | $36.86 | $39.20 | $41.69 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $36.86 | $39.20 | $41.69 | 0.00% |
| Week 2 | $35.93 | $39.20 | $42.77 | +0.01% |
| Week 3 | $35.24 | $39.20 | $43.62 | +0.01% |
| Week 4 | $34.66 | $39.20 | $44.34 | +0.01% |
| Week 5 | $34.16 | $39.21 | $44.99 | +0.01% |
| Week 6 | $33.72 | $39.21 | $45.59 | +0.02% |
| Week 7 | $33.31 | $39.21 | $46.15 | +0.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TG Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. Its lead therapy BRIUMVI is an anti-CD20 monoclonal antibody for adult patients with relapsing forms of multiple sclerosis (RMS).
The company’s development pipeline includes Ublituximab IV, glycoengineered anti-CD20 mAb for relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor; and TG-1801, a bispecific CD47 and CD19 antibody. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
TG Therapeutics, Inc. (TGTX) operates in the healthcare sector as a commercial stage biopharmaceutical company focused on B-cell mediated diseases. The stock is currently priced at $38.87, with a market cap of $5.95B and a rank of 1219 by market capitalization.
Technically, the stock shows a bullish tilt with a 30-day picture that complements a fundamental growth thesis, as reflected in the current price and ongoing development programs. Forecasts depict a rising price trajectory over the coming years, with the 2026 average price aligned near the current level and substantial upside ahead, including notable targets for 2030, 2040, and 2050 that imply meaningful long-term appreciation.
A major floor 31.3% below — a decisive break under it would weaken the trend.
The nearest floor, 14.3% below — buyers have tended to step in here.
The nearest ceiling, 10.1% above — a clean break opens room to run.
A major ceiling 23.0% above — clearing it would confirm fresh momentum.
Key TGTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TGTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $39.36 | Sell | $39.43 | Sell |
| MA 10 | $39.87 | Sell | $39.60 | Sell |
| MA 20 | $39.26 | Sell | $39.02 | Buy |
| MA 50 | $35.85 | Buy | $36.51 | Buy |
| MA 100 | $32.67 | Buy | $34.47 | Buy |
| MA 200 | $32.38 | Buy | $33.27 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.11 | Neutral |
| Stoch RSI (14) | 3.75 | Buy |
| CCI (20) | -1.68 | Neutral |
| Williams %R (14) | -92.27 | Info |
| MACD (12,26,9) | -0.41 | Sell |
| ROC (12) | -8.54 | Sell |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 7.73 | Buy |
| TRIX (15) | 0.62 | Buy |
| Awesome (5,34) | 1.68 | Buy |
| Ultimate (7,14,28) | 43.20 | Neutral |
| Momentum (10) | -3.34 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 39.13 | Buy |
| ADX (14) | 21.87 | Buy |
| ATR (14) | 0.76 | Info |
The 30-day technical picture is bullish overall. RSI14 is 50, with a 50-day simple moving average of $35.41 and a 200-day simple moving average of $32.26, suggesting positive momentum. Near-term support is at $33.58 and resistance at $43.14, providing a defined trading framework.
The stock has traded within a 30-day range of $33.14 to $45.60, and volatility remains elevated at 50% annualized. These metrics frame a constructive short-term setup while buyers and sellers gauge ongoing fundamental drivers.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.94 | $39.20 | $56.98 | 0% | Neutral | |
| $44.47 | $55.28 | $72.40 | +41% | Bullish | |
| $55.54 | $70.63 | $95.43 | +80% | Bullish | |
| $66.35 | $85.99 | $119.09 | +119% | Bullish | |
| $71.17 | $93.80 | $132.65 | +139% | Bullish | |
| $80.88 | $108.24 | $155.92 | +176% | Bullish | |
| $87.04 | $118.15 | $173.05 | +201% | Bullish | |
| $92.68 | $127.49 | $189.56 | +225% | Bullish | |
| $116.33 | $162.06 | $244.34 | +313% | Bullish | |
| $136.15 | $191.96 | $293.20 | +390% | Bullish | |
| $183.53 | $273.22 | $440.75 | +597% | Bullish | |
| $427.75 | $698.21 | $1,220.64 | +16.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $26.94 | $39.20 | $46.01 | +0.00% |
| June 2026 | $33.29 | $38.97 | $46.61 | -0.59% |
| July 2026 | $33.26 | $39.22 | $47.45 | +0.64% |
| August 2026 | $34.46 | $40.86 | $49.88 | +4.19% |
| September 2026 | $34.96 | $41.64 | $51.19 | +1.90% |
| October 2026 | $34.92 | $41.77 | $51.70 | +0.32% |
| November 2026 | $36.17 | $43.42 | $54.05 | +3.95% |
| December 2026 | $37.78 | $45.53 | $56.98 | +4.85% |
Click any year to see its month-by-month TGTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
TG Therapeutics, Inc.'s 2026 outlook centres on $39.20, within a $26.94 to $56.98 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TGTX could reach as high as $72.40, with a base case around $55.28 and support toward $44.47 — roughly +41% from $39.20. Buyers look set to stay in control over this stretch.
Expect TGTX to range from $55.54 to $95.43 through 2028. The $70.63 average target implies a +80% move from current prices. That is up +28% on the projected 2027 average. Momentum favours further upside here.
The TGTX price prediction for 2029 points to an average of $85.99 (low $66.35, high $119.09) — a potential gain of +119% on today's $39.20. Buyers look set to stay in control over this stretch.
In 2030, TGTX is projected to trade between $71.17 and $132.65, averaging $93.80 — a potential gain of +139% from today's $39.20. That is up +9% on the projected 2029 average. Momentum favours further upside here.
TG Therapeutics, Inc.'s 2031 outlook centres on $108.24, within a $80.88 to $155.92 range. That is up +15% on the projected 2030 average. That marks a +176% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TGTX could reach as high as $173.05, with a base case around $118.15 and support toward $87.04 — roughly +201% from $39.20. Momentum favours further upside here.
Expect TGTX to range from $92.68 to $189.56 through 2033. The $127.49 average target implies a +225% move from current prices. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The TGTX price prediction for 2034 points to an average of $162.06 (low $116.33, high $244.34) — a potential gain of +313% on today's $39.20. Momentum favours further upside here.
In 2035, TGTX is projected to trade between $136.15 and $293.20, averaging $191.96 — a potential gain of +390% from today's $39.20. That is up +18% on the projected 2034 average. Buyers look set to stay in control over this stretch.
TG Therapeutics, Inc.'s 2040 outlook centres on $273.22, within a $183.53 to $440.75 range. That is up +42% on the projected 2035 average. That marks a +597% change versus current levels. Momentum favours further upside here.
By 2050, TGTX could reach as high as $1,220.64, with a base case around $698.21 and support toward $427.75 — roughly +16.8x from $39.20. Buyers look set to stay in control over this stretch.
Investing $1,000 in TGTX today (≈ 25.510204 TGTX) could be worth
$17,811.45
+$16,811.45 (+1681%) by 2050 · US Dollar
Based on the average projected TGTX price of $698.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TGTXwould be worth at today's price.
$1,000 invested in TGTX on May 27, 2025 (≈ 28.376843 TGTX) would be worth
$1,112.37
+$112.37 (+11.2%) today · 1.11× · US Dollar
Based on a TGTX entry price of $35.24 vs. today's $39.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $39.76 | $985.92 | -1.4% |
| 1 month ago | $35.38 | $1,107.97 | +10.8% |
| 3 months ago | $30.9 | $1,268.61 | +26.9% |
| 6 months ago | $33.26 | $1,178.59 | +17.9% |
| 1 year ago | $35.24 | $1,112.37 | +11.2% |
| All time (5.0y) ago | $34.46 | $1,137.55 | +13.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TGTX forecast.
Our base-case forecast reaches $78.00 around 2029.
Implied market cap at $78.00: $11.94B
The multi-year forecast shows a strong bullish trajectory across the horizon. In 2026, the average price is $38.87 with an ROI of 0% and sentiment Neutral. By 2027, the average is $57.59 with an ROI of 48.1% and bullish sentiment, and it climbs further in subsequent years.
By 2030, the average price is $102.56 with a max of $146.14 and a min of $77.34, delivering an ROI of 163.9% and bullish sentiment. The forecast continues to rise through 2040 to an average of $335.30 (max $547.08, min $222.53) with ROI of 762.6% and bullish sentiment, and into 2050 with an average of $884.25 (max $1,566.94, min $532.52) and ROI of 2174.9% with bullish sentiment. These targets show the potential for substantial upside over the long term, but they come with wide ranges (min/max) and are not guarantees.
The volatility figure (50% annualized) underscores the inherent uncertainty and risk in long-horizon forecasts.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $102.56 with a min of $77.34 and a max of $146.14, and an ROI of 163.9% with bullish sentiment.
Forecasts show bullish sentiment from 2027 onward with rising averages. By 2030 the average is $102.56 and ROI is 163.9%; by 2040 the average is $335.30 with ROI 762.6%; by 2050 the average is $884.25 with ROI 2174.9%. These are estimates and not guarantees.
Yes. The 2030 forecast lists an average of $102.56 and a max of $146.14, with a min of $77.34, indicating a path that crosses and exceeds $100 in the forecast horizon.
For 2040, the forecasted average price is $335.30, with a min of $222.53 and a max of $547.08; ROI is 762.6 and sentiment is bullish.
For 2050, the forecasted average price is $884.25, with a min of $532.52 and a max of $1,566.94; ROI is 2174.9 and sentiment is bullish.
TG Therapeutics, Inc. Community Discussion
0Share your TG Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.